Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent recombinant influenza vaccine H3 strain 1
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A quadrivalent recombinant influenza vaccine containing the H3 strain is a **recombinant protein-based vaccine** designed for **active immunization against influenza**. This vaccine technology uses recombinant DNA techniques to generate the hemagglutinin (HA) protein of four influenza virus strains (including an H3N2 strain) without the need for live influenza virus or eggs. The HA gene from the target strain is engineered into a baculovirus, which is used to infect insect or other cell cultures. These cells express large quantities of the HA protein, which is harvested and purified to formulate the vaccine. The primary mechanism is the induction of protective antibodies against the viral HA, preventing virus entry into human cells. Quadrivalent formulations target two influenza A strains (including H3N2) and two influenza B strains, for broad seasonal coverage. The vaccine is non-live and cannot cause influenza. It is indicated for use in appropriate age groups as determined by licensing authorities.
- Other names
- quadrivalent recombinant influenza vaccine H3 strain 1
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on quadrivalent recombinant influenza vaccine H3 strain 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent recombinant influenza vaccine H3 strain 1.